| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/SMIM.1998.0156 |
| P698 | PubMed publication ID | 9826579 |
| P2093 | author name string | Watanabe T | |
| Horie R | |||
| P433 | issue | 6 | |
| P304 | page(s) | 457-470 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Seminars in Immunology | Q15762658 |
| P1476 | title | CD30: expression and function in health and disease | |
| P478 | volume | 10 |
| Q37372827 | A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma |
| Q36294776 | A scalable approach to prevent teratoma formation of human embryonic stem cells |
| Q39392332 | AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells |
| Q33617937 | Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata |
| Q42508366 | Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease |
| Q39117761 | Acute myeloid leukemia targets for bispecific antibodies |
| Q48528844 | Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. |
| Q92890008 | Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients |
| Q92886775 | Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models |
| Q46095776 | Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy. |
| Q92802178 | Bioinformatics analysis of whole slide images reveals significant neighborhood preferences of tumor cells in Hodgkin lymphoma |
| Q38311211 | Biostable ssDNA aptamers specific for Hodgkin lymphoma |
| Q92089375 | Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors |
| Q50542308 | CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms. |
| Q41921207 | CD30 Is Dispensable for T-Cell Responses to Influenza Virus and Lymphocytic Choriomeningitis Virus Clone 13 but Contributes to Age-Associated T-Cell Expansion in Mice |
| Q55500218 | CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling. |
| Q38950501 | CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas |
| Q34300698 | CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes |
| Q39856756 | CD30 expression reveals that culture adaptation of human embryonic stem cells can occur through differing routes |
| Q40311485 | CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells |
| Q39636232 | CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease |
| Q52645848 | CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma. |
| Q40416864 | CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism |
| Q33841251 | Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy |
| Q64055595 | Challenges of driving CD30-directed CAR-T cells to the clinic |
| Q36505738 | Deciphering CD30 ligand biology and its role in humoral immunity |
| Q95841197 | Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma |
| Q84101046 | Different role of CD30 in the development of acute and chronic airway inflammation in a murine asthma model |
| Q58494388 | Differential expression of genes encoding CD30L and P-selectin in cattle with Johne's disease: Progress toward a diagnostic gene expression signature |
| Q35642843 | Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease |
| Q35878906 | Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation |
| Q40870263 | Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. |
| Q40594788 | Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma |
| Q36942675 | Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors |
| Q35788035 | Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms |
| Q38510630 | Genotype-dependent tumor regression in Marek's disease mediated at the level of tumor immunity. |
| Q28207526 | Hodgkin's lymphoma and CD30 signal transduction |
| Q40674024 | Human CD30: structural implications from epitope mapping and modeling studies |
| Q38732770 | Human T-cell lymphotropic virus type 1 and its oncogenesis |
| Q34707404 | Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma |
| Q35122971 | Identification of novel genes associated with renal tertiary lymphoid organ formation in aging mice |
| Q33518060 | Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda |
| Q34122409 | Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment |
| Q37006427 | Immunotherapies for Hodgkin's lymphoma |
| Q39106578 | Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer |
| Q34038795 | Importance of CD4(+) T helper cell responses in tumor immunity. |
| Q47407977 | Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group |
| Q51734429 | Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. |
| Q36371279 | Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus |
| Q40736248 | Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells |
| Q37535521 | Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30) |
| Q64063826 | Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies |
| Q35017864 | Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion |
| Q36512063 | Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies |
| Q36569720 | Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis |
| Q38874169 | Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review |
| Q34655256 | Microtubule inhibitor-based antibody-drug conjugates for cancer therapy |
| Q24535231 | Monoclonal antibodies |
| Q37701472 | New targets of therapy in T-cell lymphomas |
| Q33793521 | Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients, part II: omics analyses of urine and blood samples |
| Q92001956 | Plasma Factors for the Differentiation of Hodgkin's Lymphoma and Diffused Large B Cell Lymphoma and for Monitoring Remission |
| Q86234341 | Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study |
| Q83344990 | Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30 |
| Q91927508 | Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes |
| Q24633761 | Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma |
| Q35880592 | Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. |
| Q28591321 | Several different cell surface molecules control negative selection of medullary thymocytes |
| Q81813237 | Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection |
| Q43466537 | Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft |
| Q33957705 | Strategies for immunotherapy of cancer |
| Q27005694 | Subversion of cytokine networks by virally encoded decoy receptors |
| Q40782944 | Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack. |
| Q35183220 | Systemic and primary cutaneous anaplastic large cell lymphomas |
| Q36331757 | T cell subtypes and reciprocal inflammatory mediator expression differentiate P. falciparum memory recall responses in asymptomatic and symptomatic malaria patients in southeastern Haiti |
| Q30743828 | TNF ligands and receptors in autoimmunity: an update |
| Q74840082 | TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice |
| Q35125212 | TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation |
| Q37412853 | Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin |
| Q38052082 | Targeting CD30 in anaplastic large cell lymphoma |
| Q44848855 | The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma |
| Q57177485 | The application of CAR-T cell therapy in hematological malignancies: advantages and challenges |
| Q24683018 | The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games |
| Q35222365 | The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy. |
| Q39663897 | The side population, as a precursor of Hodgkin and Reed‐Sternberg cells and a target for nuclear factor‐κB inhibitors in Hodgkin’s lymphoma |
| Q33816812 | Thymocyte apoptosis |
| Q54960332 | Toxoplasmosis submandibular lymphadenitis: Report of an unusual case with a brief review. |
| Q36358059 | Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. |
| Q36380499 | Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity |
| Q47102763 | Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions |
| Q57802286 | Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma |
| Q38892631 | Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility |
Search more.